{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:28:49Z","timestamp":1744777729015},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,9,15]]},"DOI":"10.2169\/internalmedicine.6917-20","type":"journal-article","created":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T22:06:53Z","timestamp":1616969213000},"page":"3025-3029","source":"Crossref","is-referenced-by-count":13,"title":["Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma"],"prefix":"10.2169","volume":"60","author":[{"given":"Yoshitaka","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Department of Neurology, Yamagata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Aso","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Yamagata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yamagata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yamagata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12: 738, 2020.","DOI":"10.3390\/cancers12030738"},{"key":"2","unstructured":"2. Brahmer JR, Lacchetti C, Schneider BJ, et al.; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158-168, 2018.","DOI":"10.1056\/NEJMra1703481"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sheik Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151: 195-199, 201.","DOI":"10.1001\/jamadermatol.2014.2233"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yamaguchi Y, Abe R, Haga N, Shimizu H. A case of drug-associated dermatomyositis following ipilimumab therapy. Eur J Dermatol 26: 320-321, 2016.","DOI":"10.1684\/ejd.2016.2770"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kudo F, Watanabe Y, Iwai Y, et al. Advanced lung adenocarcinoma with nivolumab-associated dermatomyositis. Intern Med 57: 2217-2221, 2018.","DOI":"10.2169\/internalmedicine.9381-17"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kadota H, Gono T, Shirai Y, Okazaki Y, Takeno M, Kuwana M. Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr Rheumatol Rep 21: 10, 2019.","DOI":"10.1007\/s11926-019-0811-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shibata C, Kato J, Toda N, et al. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report. J Med Case Rep 13: 168, 2019.","DOI":"10.1186\/s13256-019-2105-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kD nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46: 25-28, 2007.","DOI":"10.1093\/rheumatology\/kel161"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64: 513-522, 2012.","DOI":"10.1002\/art.33403"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344-347, 1975.","DOI":"10.1056\/NEJM197502132920706"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Rittmeyer A, Barlesi F, Waterkamp D, et al.; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017.","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Socinski MA, Jotte RM, Cappuzzo F, et al.; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378: 2288-2301, 2018.","DOI":"10.1056\/NEJMoa1716948"},{"key":"14","unstructured":"14. Brahmer JR, Lacchetti C, Schneider BJ, et al.; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36: 1714-1768, 2018."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 22: 347-352, 2010.","DOI":"10.1093\/intimm\/dxq030"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124: 188-195, 2014.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tanaka R, Okiyama N, Okune M, et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor \u03b1 is a biomarker of nivolumab recativity. J Dermatol Sci 86: 71-73, 2017.","DOI":"10.1016\/j.jdermsci.2016.12.019"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Naqash AR, Yang LV, Sanderlin EJ, Atwell DC, Walker PR. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncologica 57: 705-708, 2018.","DOI":"10.1080\/0284186X.2017.1406668"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer 64: 2017.","DOI":"10.1002\/pbc.26642"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sakakida T, Ishikawa T, Chihara Y, et al. Safety and efficacy of PD-1\/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol 22: 919-927, 2020.","DOI":"10.1007\/s12094-019-02214-8"},{"key":"21","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"21. Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology 53: 2196-2203, 2014.","journal-title":"Rheumatology","ISSN":"http:\/\/id.crossref.org\/issn\/1460-2172","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60: 3436-3446, 2009.","DOI":"10.1002\/art.24936"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediate adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 25: 551-557, 2019.","DOI":"10.1177\/1078155217745144"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/18\/60_6917-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T03:19:54Z","timestamp":1631935194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/18\/60_6917-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":23,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6917-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"article-number":"6917-20"}}